Consolidated Statements of Operations and Comprehensive Loss - USD ($) |
3 Months Ended | |
|---|---|---|
Feb. 29, 2020 |
Feb. 28, 2019 |
|
| Revenues | ||
| Licensing (Note 3) | $ 377,554 | $ 264,551 |
| Up-front fees (Note 3) | 0 | 78,985 |
| Revenues | 377,554 | 343,536 |
| Cost of goods sold | 0 | 33,068 |
| Gross margin | 377,554 | 310,468 |
| Expenses | ||
| Research and development | 947,845 | 2,132,261 |
| Selling, general and administrative | 523,231 | 1,207,243 |
| Depreciation (Note 4) | 102,699 | 125,284 |
| Expenses | 1,573,775 | 3,464,788 |
| Loss from operations | (1,196,221) | (3,154,320) |
| Net foreign exchange (loss) gain | 22,788 | (11,332) |
| Interest income | 0 | 11 |
| Interest expense | (573,940) | (58,808) |
| Net loss and comprehensive loss | $ (1,747,373) | $ (3,224,449) |
| Loss per common share, basic and diluted | $ (.08) | $ (.16) |
| Weighted average number of common shares outstanding, basic and diluted | 23,210,297 | 20,058,207 |